Page last updated: 2024-12-09

sclareolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sclareolide: has antineoplastic activity; synthesized by oxidation of sclareol; a minor constituent of Arnica angustifolia and Sideritis nutans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
SideritisgenusA plant genus of the family LAMIACEAE that contains isoscutellarein-7-O-(allosyl(1-2)glucoside).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]
ArnicagenusA plant genus of the family ASTERACEAE. The dried flower heads of Arnica montana are used externally as a counterirritant and tincture for sprains and bruises, either as crude extract or in homeopathic dilution (HOMEOPATHY). Arnica contains volatile oils (OILS, VOLATILE), arnicin, arnisterol, FLAVONOIDS; TANNINS; and resin. The common name of Wolf's Bane is similar to the common name for ACONITUM.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Arnica angustifoliaspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
SideritisgenusA plant genus of the family LAMIACEAE that contains isoscutellarein-7-O-(allosyl(1-2)glucoside).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]
ArnicagenusA plant genus of the family ASTERACEAE. The dried flower heads of Arnica montana are used externally as a counterirritant and tincture for sprains and bruises, either as crude extract or in homeopathic dilution (HOMEOPATHY). Arnica contains volatile oils (OILS, VOLATILE), arnicin, arnisterol, FLAVONOIDS; TANNINS; and resin. The common name of Wolf's Bane is similar to the common name for ACONITUM.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Arnica angustifoliaspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID5341010
SCHEMBL ID13223919
MeSH IDM0283904
PubMed CID929262
CHEMBL ID304461
CHEBI ID156168
SCHEMBL ID83395
MeSH IDM0283904

Synonyms (68)

Synonym
CBMICRO_025045
5570-44-5
BIM-0025019.P001
AC1NSWYM ,
sclareolide
CCG-12079
SCHEMBL13223919
DTXSID80416963
(3ar)-(+)-sclareolide, 97%
(3ar)-(+)-sclareolide
NCGC00163620-01
564-20-5
smr000538921
MLS001173371 ,
norambreinolide
(3ar,5as,9as,9br)-3a,6,6,9a-tetramethyl-1,4,5,5a,7,8,9,9b-octahydrobenzo[e][1]benzouran-2-one
CHEBI:156168
CHEMBL304461
(+)-sclareolide
HMS2860M07
(3ar,5as,9as,9br)-3a,6,6,9a-tetramethyl-1,4,5,5a,7,8,9,9b-octahydrobenzo[e][1]benzofuran-2-one
NCGC00256856-01
cas-564-20-5
dtxsid8047686 ,
dtxcid6027686
tox21_302544
S0847
SCLAREOLIDE - NORAMBREINOLIDE
(3ar-(3aalpha,5abeta,9aalpha,9bbeta))decahydro-3a,6,6,9a-tetramethylnaphth(2,1-b)furan-2(1h)-one
norambreinolide, (+)-
3a,4,5,5aalpha,6,7,8,9,9a,9balpha-decahydro-3abeta,6,6,9abeta-tetramethylnaphtho(2,1-b)furan-2(1h)-one
naphtho(2,1-b)furan-2(1h)-one, decahydro-3a,6,6,9a-tetramethyl-, (3ar,5as,9as,9br)-
einecs 209-269-0
12-norambreinolide
naphtho(2,1-b)furan-2(1h)-one, 3a,4,5,5aalpha,6,7,8,9,9a,9balpha-decahydro-3abeta,6,6,9abeta-tetramethyl-
naphtho(2,1-b)furan-2(1h)-one, decahydro-3a,6,6,9a-tetramethyl-, (3ar-(3aalpha,5abeta,9aalpha,9bbeta))-
unii-37w4o0o6e6
decahydrotetramethylnaphthofuranone
37w4o0o6e6 ,
fema no. 3794
sclareolide [fhfi]
sclareolide [inci]
AKOS015901397
S2355
CCG-208493
SCHEMBL83395
IMKJGXCIJJXALX-SHUKQUCYSA-N
cid_929262
bdbm75178
(3ar,5as,9as,9br)-3a,6,6,9a-tetramethyl-1,4,5,5a,7,8,9,9b-octahydrobenzo[e]benzofuran-2-one
mfcd00134168
(3a,r)-(+)-sclareolide
sr-01000812893
SR-01000812893-3
(3ar,5as,9as,9br)-3a,6,6,9a-tetramethyldecahydronaphtho[2,1-b]furan-2(1h)-one
(3ar)-(+)-sclareolide, analytical standard
(3ar)-(+)-sclareolide, natural, 97%, fg
NCGC00163620-03
(3ar,5as,9as,9br)-decahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan-2(1h)-one
DS-7369
HY-N0129
sclareolide (norambreinolide)
clareolide
BRD-K72925150-001-11-1
CS-0007855
A869953
H10516
clary sage lactone

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthofuran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency54.94770.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency54.94770.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency36.95750.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency51.11450.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
progesterone receptorHomo sapiens (human)Potency24.33650.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.99640.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.89300.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency30.63790.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.79610.000229.305416,493.5996AID1259244; AID743069; AID743078
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.13060.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency21.83380.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.652419.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency51.87400.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency53.45710.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency38.57080.000627.21521,122.0200AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_bHomo sapiens (human)EC50 (µMol)500.00000.918141.9368121.5000AID435026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID92582Percentage inhibition against growth factor induced tube formation by human umbilical vein endothelial cells (HUVEC) at 10 ug/mL concentration; NT: Not tested2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide.
AID1596088Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 0.1 uM incubated for 18 hrs by celltiter-glo luminescent assay relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596098Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 20 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID92563Growth inhibitory activity against human umbilical vein endothelial cells (HUVEC) proliferation using MTT colorimetric method2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide.
AID1596087Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1356585Cytotoxicity against mouse BV2 cells assessed as cell viability at 20 uM measured after 24 hrs by MTT assay relative to control2018Journal of natural products, 08-24, Volume: 81, Issue:8
Structural Characterization of Terpenoids from Abies holophylla Using Computational and Statistical Methods and Their Biological Activities.
AID1596095Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 0.1 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596090Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 1 uM incubated for 18 hrs by celltiter-glo luminescent assay relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1596093Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 5 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596096Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 1 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596091Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 5 uM incubated for 18 hrs by celltiter-glo luminescent assay relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1356584Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Structural Characterization of Terpenoids from Abies holophylla Using Computational and Statistical Methods and Their Biological Activities.
AID1596086Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 0.1 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596092Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 20 uM incubated for 18 hrs by celltiter-glo luminescent assay relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596097Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 5 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID1596094Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 20 uM pretreated for 1 hr followed by LPS stimulation and measured after 18 hrs by ELISA relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.04)18.2507
2000's17 (34.69)29.6817
2010's19 (38.78)24.3611
2020's12 (24.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.12 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index57.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]